| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 83.7 Billion |
| Market Size in 2026 | USD 88.6 Billion |
| Market Size by 2032 | USD 130.7 Billion |
| Projected CAGR | 6.6% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Fragmented |
Explore the market potential with our data-driven report
The biobanking market size was USD 83.7 billion for 2025, and it will grow by 6.6% during 2026–2032, to reach USD 130.7 billion by 2032.
This growth is driven by escalating demand for high-quality biological specimens across precision medicine, translational research, and next-generation drug discovery pipelines, positioning biobanks as critical cornerstones of contemporary biomedical infrastructure. Accelerating adoption of genomic medicine, combined with heightened pharmaceutical investment in biospecimen-dependent clinical trial programs, is reinforcing the strategic importance of well-curated biological repositories across healthcare systems worldwide.
The convergence of population-scale genomics programs and chronic disease research is intensifying biosample demand at an unprecedented rate. Institutional demand for standardized, high-integrity biospecimen repositories is increasing as translational research timelines compress and biomarker-driven therapeutic development becomes more data-intensive. For instance, the National Institutes of Health (NIH) reports that its All of Us Research Program biobank has processed over 3.8 million primary biospecimen collections, generating more than 14 million aliquoted samples that support genomic diversity studies and federally funded biomarker research across the United States.
The integration of laboratory information management systems (LIMS), robotic sample-handling platforms, artificial intelligence-driven quality control, and cloud-based biospecimen data analytics is fundamentally redefining biobank operational capabilities, scalability, and scientific utility. Manual biobanking processes, historically subject to sample identification errors, freeze-thaw inconsistencies, and metadata gaps, are being replaced by automated workflows that dramatically improve throughput, data accuracy, and biospecimen traceability across large-scale repositories.
The growing scale of multi-omic research further illustrates this shift. For example, the U.S. National Heart, Lung, and Blood Institute (NHLBI) reports that its Trans-Omics for Precision Medicine program has sequenced nearly 200,000 whole genomes from diverse populations, generating multi-omic datasets that require integrated LIMS, automated biospecimen handling, and AI-driven analytics platforms to manage and disseminate at scale. This digital transformation trend is elevating the software and services segments of the biobanking market relative to traditional hardware, as biobanks shift from one-time capital purchases toward recurring digital subscription models and managed services contracts.
National governments across North America, Europe, and Asia-Pacific are directly catalyzing biobanking market growth through taxpayer-funded population genomics cohorts, disease registries, and precision medicine biobanks that require sustained investment in specimen collection, cryogenic storage, processing equipment, consumables, and data management platforms. These programs structurally increase demand across all market segments, from manual and automated storage systems to laboratory information management software and cold-chain logistics services.
The National Institutes of Health (NIH) has committed up to USD 50 million in FY 2025 to fund the continuation and expansion of the All of Us Research Program Biobank. In Europe, the UK Biobank has enrolled over 500,000 participants with linked genomic, imaging, and longitudinal health data, serving as one of the most extensively characterized population-scale biorepositories globally and driving sustained investment in sample storage and data infrastructure. In Asia, Japan’s Biobank Japan project has collected biological samples from more than 200,000 patients across multiple disease categories, reinforcing long-term government support for disease-specific genomic research and structured biospecimen procurement programs. These programs collectively represent sustained multi-year procurement cycles for biobanking equipment, consumables, and services, providing commercial vendors with long-duration revenue visibility that underpins strategic capacity expansion and R&D investment in the sector.
A critical structural gap in the global biobanking landscape is the significant underrepresentation of genetically and clinically diverse biospecimens from populations in Asia, Africa, Latin America, and the Middle East, where the majority of the world's disease burden resides, but biorepository infrastructure remains nascent. Population genomics research has consistently demonstrated that most existing biobank collections disproportionately represent individuals of European ancestry, limiting the generalizability of precision medicine discoveries to global patient populations. In May 2024, EIT Health launched a Biobanks and Health Data Registries platform in collaboration with BBMRI-ERIC, aimed at improving cross-border discoverability and structured access to European biospecimen collections, reinforcing institutional efforts to broaden population representation in biomedical research.
This diversity deficit creates a commercially significant pathway for biorepository operators, equipment suppliers, and service providers to establish infrastructure in underserved regions where government health investment is accelerating. The NIH All of Us Research Program was specifically designed to collect biospecimens and health data from 1 million individuals across racial, ethnic, and socioeconomic groups historically underrepresented in biomedical research, prioritizing longitudinal genomic, lifestyle, and environmental data collection to build a more equitable biospecimen resource for global science.
The equipment category holds the largest market share, of 45%, in 2025, driven by the capital-intensive nature of biorepository infrastructure, where ultra-low temperature freezers, cryogenic storage systems, liquid nitrogen tanks, and automated robotic sample-handling platforms represent one-time high-value purchases essential to any functional biobank. The persistent expansion of new biobanks across national genomics programs, pharmaceutical companies, and academic medical centers creates consistent first-purchase demand for specialized equipment, underpinning this segment's sustained revenue dominance. Additionally, Thermo Fisher Scientific, Inc., in April 2024, introduced the TSX Universal Series ENERGY STAR-certified ultra-low temperature freezers, engineered to deliver tighter temperature control, accelerated thermal recovery times, and enhanced energy efficiency across diverse laboratory and biorepository workflows.
The software category will have the highest CAGR, of 7.0%, reflecting the systemic shift of biobank operations from physical sample management toward data-driven, digitally integrated workflows. LIMS, cloud-based biospecimen tracking platforms, and AI-powered quality control software are increasingly positioned as mandatory operational infrastructure rather than optional tools, generating recurring subscription revenue at rates that outpace equipment replacement cycles. The National Cancer Institute's Biorepositories and Biospecimen Research Branch directs development of standardized procedures and digital informatics resources, including the publicly accessible Biospecimen Research Database, affirming government-level validation of software-driven biobank management as best practice.
The offerings analyzed in this report are:
The blood products and genetic material category holds the largest market share, of 40%, in 2025, supported by the standardized, well-established collection protocols that make blood-derived specimens the most operationally accessible and analytically versatile biospecimen class available to researchers. Blood samples enable a wide spectrum of downstream applications including serology, hematology, genomics, metabolomics, and immune profiling, ensuring consistently high institutional demand across clinical research, pharmacogenomics, and large-scale epidemiological studies alike. The National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Biospecimen Banks maintain a structured collection of blood products and genetic material linked to detailed clinical outcome data from NCI-funded Phase II–III cancer trials, making blood-based biospecimens integral to government-sponsored biomarker discovery and validation programs at scale.
The cell lines category will have the highest CAGR, fueled by the rapid expansion of autologous and allogeneic cell and gene therapy pipelines that require rigorously characterized, GMP-compliant cell substrates for clinical application. Induced pluripotent stem cell lines, cancer cell lines, and primary immune cell populations are in escalating demand as biopharmaceutical companies advance CRISPR-based therapies, CAR-T programs, and advanced tissue engineering applications requiring certified biospecimen inputs.
The sample types analyzed in this report are:
The manual category holds the larger market share, of 75%, in 2025, reflecting the operational reality that the majority of the world's active biobanks, particularly those within academic institutions, hospital systems, regional government biorepositories, and lower-income country health programs, rely on conventional manually operated ultra-low temperature freezers, cryogenic tanks, and ambient-temperature storage systems. The lower capital cost and simpler infrastructure requirements of manual storage solutions allow smaller and mid-scale biobanks to maintain biospecimen collections without the significant investment associated with full automation. The U.S. Centers for Disease Control and Prevention maintains national biospecimen collection and storage programs within its disease surveillance infrastructure, relying on standardized cold-chain storage protocols representative of conventional biobank operations.
The automated category will have the higher CAGR, of 6.9%, propelled by the increasing need for high-throughput, error-minimized sample retrieval in large-volume repositories, pharmaceutical biorepositories, and high-throughput clinical trial sample collections that exceed the practical capacity and accuracy limits of manual workflows. Robotic sample-retrieval systems, high-density automated storage platforms, and integrated LIMS-driven workflows dramatically reduce freeze-thaw cycles, human handling errors, and sample degradation risk while enabling 24/7 operational throughput. In February 2024, Azenta, Inc. launched the BioArc Ultra, an advanced automated ultracold sample management system engineered for high-density, energy-efficient large-scale biorepository operations, reflecting accelerating commercial innovation in automation-driven storage platforms.
The storage types analyzed in this report are:
The clinical research category holds the largest market share, of 55%, in 2025, supported by protocol-driven biospecimen collection requirements embedded within multicenter clinical trial frameworks. The NCI's Biospecimen Banks support the National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP), collectively enrolling thousands of cancer patients annually whose biospecimens are collected under harmonized protocols and distributed globally for biomarker development, pharmacokinetic studies, and translational cancer research applications.
The regenerative medicine category will have the highest CAGR, driven by the accelerating clinical translation of cell therapies, tissue engineering platforms, and gene-editing approaches that rely on biobanked stem cells, iPSC lines, and primary cell substrates as foundational research inputs. Global regulatory authorities, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), have reported a sustained increase in clinical development activity for advanced cell and gene therapies, which require rigorously preserved, well-characterized, and traceable biospecimens to support clinical development, manufacturing validation, and regulatory submission processes.
The applications analyzed in this report are:
The research category holds the largest market share, of 60%, in 2025, driven by the expansive and sustained volume of basic science, translational, and preclinical investigations that depend on well-annotated biospecimen access across academia, government research institutes, and pharmaceutical R&D programs. The NIH Genotype-Tissue Expression project, supported by the NIH Common Fund, collects and analyzes donated human biospecimens from deceased donors to form a publicly accessible tissue bank and research database that enables the study of human genetic variation and inherited disease susceptibility, a flagship example of research-utility biobanking at national scale.
The epidemiology category will have the highest CAGR, of 6.7%, as governments and international health organizations increasingly invest in population-wide biospecimen cohorts to monitor chronic disease trajectories, identify risk biomarkers at population scale, and design precision public health interventions. The WHO Global Health Observatory estimates that noncommunicable diseases now account for 74% of all global deaths annually, creating institutional urgency for large-scale, epidemiology-focused biobanks capable of linking longitudinal biological data to disease incidence and health outcome records.
The utilities analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 40%, in 2025, securing regional dominance through a combination of federally funded biospecimen repositories, mature research infrastructure, and deep pharmaceutical industry-academia partnerships. The United States serves as the primary market engine, supported by sustained National Institutes of Health investment across population genomics programs, disease-focused biorepositories, and clinical biomarker grants. The President’s FY 2026 budget request includes USD 27.5 billion in discretionary funding for NIH, reinforcing the scale of federal support for biomedical research infrastructure.
Canada complements regional leadership through publicly funded provincial biobank networks and internationally affiliated university research hospitals. The Government of Canada supports large-scale population biobanking through initiatives such as the Canadian Partnership for Tomorrow’s Health, which has enrolled over 330,000 participants across multiple provincial cohorts, creating one of the largest population health research platforms in the country.
High-volume pharmaceutical and biotechnology R&D activity across the region generates consistent demand for well-annotated biospecimens, particularly in oncology, cardiovascular disease, and rare therapeutic development pipelines. Public investment in biospecimen infrastructure across both countries continues to attract private-sector co-investment, reinforcing the region's long-term leadership position.
The U.S. dominated North American biobanking revenue in 2025, driven by its well-established network of federal repositories, academic biobanks, hospital-based collections, and commercial biorepository operators. Government-funded programs, including the All of Us Research Program, the National Cancer Institute (NCI) biospecimen repositories, and the Veterans Affairs Million Veteran Program, collectively curate hundreds of millions of biological samples and establish unrivaled infrastructure depth. The Consolidated Appropriations Act, 2026, provides the NCI with approximately USD 7.35 billion in funding for fiscal year 2026, reflecting an increase of about USD 128 million compared with FY 2025 and reinforcing sustained federal support for oncology, genomics, and cancer biomarker research nationwide.
Asia-Pacific will have the highest CAGR, of 6.8%, driven by large-scale government-backed genomic programs, a rapidly rising chronic disease burden, and expanding biopharmaceutical R&D infrastructure. China, India, Japan, and South Korea are collectively investing in population genomics at a scale that increasingly rivals established Western markets. National precision medicine initiatives and public health genomics programs are generating high-volume demand for diverse, genetically rich biospecimen repositories across the region. China’s National GeneBank in Shenzhen, among the world’s largest biological sample repositories, exemplifies the country’s state-funded large-scale biobanking infrastructure. The China Kadoorie Biobank includes over 510,000 adult participants with longitudinal health tracking, strengthening the region’s population-scale biospecimen research capacity.
Similarly, a peer-reviewed study published in PubMed Central (2025) reports that South Korea’s National Project of Bio-Big Data aims to recruit 1 million participants between 2024 and 2032, highlighting the expanding scale of government-backed genomic and biobank initiatives across East Asia. Growing pharmaceutical outsourcing activity and the rapid expansion of clinical trial infrastructure throughout Southeast Asia are further widening the regional biobanking market base, attracting multinational biorepository operators and specialized equipment suppliers.
Europe constituted approximately 30% of global biobanking market share in 2025, reflecting a mature ecosystem supported by coordinated research infrastructure, structured regulatory oversight, and strong academic–industry collaboration. The Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium (BBMRI-ERIC) brings together national biobank nodes across 23 European member countries and one international organisation, forming one of the largest coordinated biobanking research infrastructures globally. This pan-European integration enhances standardized access to biospecimens, promotes cross-border data sharing, and strengthens interoperability across national repositories.
Germany, the U.K., France, and the Nordic nations collectively host some of the world's most extensive population-based biobanks, delivering longitudinally annotated sample collections for pharmaceutical and academic research. European regulatory frameworks, including GDPR and the European Health Data Space Regulation (Regulation 2025/327), are reshaping biobank data governance by mandating harmonized consent structures and enabling structured secondary use of biospecimen and health data across EU member states.
Additionally, stringent European regulatory standards for traceability and GMP compliance are elevating demand for advanced biorepository infrastructure across the region. The International Agency for Research on Cancer projects that new cancer cases in Europe will rise by approximately 22.5% over the next two decades, reinforcing sustained demand for oncology-focused biobank infrastructure as precision medicine programs continue to scale across the region.
The regions and countries of the market are as follows:
The market is fragmented, driven by the market's inherent breadth across multiple distinct product and service categories, specimen storage equipment, consumables, cryogenic logistics, laboratory information management software, and specialized services, which prevent any single company from holding dominant share across the entire value chain. Within this fragmented landscape, a cluster of diversified life science and laboratory technology corporations maintains the most comprehensive market presence by offering integrated portfolios spanning specimen collection consumables, automated cold-chain storage systems, LIMS platforms, and cryogenic logistics services. Additionally, regional and niche-focused providers continue to maintain competitive relevance by specializing in disease-specific biorepositories, advanced cryogenic infrastructure, or tailored sample management solutions across localized markets.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages